" /> SARS coronavirus 2 spike protein RBD Ab.neut:PrThr:Pt:Ser/Plas:Ord:sVNT - CISMeF





Preferred Label : SARS coronavirus 2 spike protein RBD Ab.neut:PrThr:Pt:Ser/Plas:Ord:sVNT;

LOINC status : ACTIVE;

LOINC display name : SARS-CoV-2 (COVID-19) S protein RBD neut ab sVNT Ql;

LOINC long common name : SARS-CoV-2 (COVID-19) S protein RBD neutralizing antibody [Presence] in Serum or Plasma by sVNT;

LOINC short name : SARS-CoV-2 S RBD NAb SerPl Ql sVNT;

LOINC description : Qualitative results for detection of neutralizing antibodies (NAbs) that block the binding of the S (spike) protein receptor binding domain (RDB) from SARS Coronavirus 2 (SARS-CoV-2) to ACE2 receptor protein in serum or plasma specimens by surrogate virus neutralization testing (sVNT), which is an immunoassay-based method. Neutralizing antibody testing is performed to determine whether the antibodies produced after SARS-CoV-2 infection or in response to a vaccination are able to neutralize the virus and prevent infection or re-infection. Different methods can be used to determine the presence of neutralizing antibodies, including conventional VNT (virus neutralization test, cVNT), pseudovirus VNT (pVNT), and surrogate VNT (sVNT). The sVNT method currently employs purified proteins in an immunoassay-based format, takes less time to complete, and does not require the use of live virus compared to cVNT and pVNT methods.;

Details


You can consult :


Nous contacter.
28/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.